Probity Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
TP
Probity Advisors's MRNA Position: Q3 2026 in Review
Probity Advisors reduced its Moderna (MRNA) stake by 7.3% in Q3 2026, selling an estimated $70K and leaving 8,297 shares worth $1.6M. The position accounts for 0.23% of the portfolio, ranked #76.
Probity Advisors first reported a position in MRNA in Q1 2024 and has held it in 11 quarters since. 1,048 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.
- Probity Advisors held 8,297 shares of Moderna worth $1.6M as of Q3 2026.
- Probity Advisors sold 650 Moderna shares in Q3 2026, an estimated $70K.
- Moderna made up 0.23% of Probity Advisors's portfolio in Q3 2026, its #76 holding.
- Probity Advisors first reported a position in Moderna in Q1 2024 and has held it in 11 quarters since.
- 1,048 funds tracked by Wall St. Rank held Moderna as of Q3 2026.
Based on Probity Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.